The objective of this work was to investigate the mechanisms of hepatobiliary toxicity caused by thienopyrimidone MCHR1 antagonists using BMS-773174 as a tool molecule. Co-administration of the pan CYP inhibitor 1-aminobenzotriazole with BMS-773174 prevented hepatobiliary damage, and direct delivery of the diol metabolite BMS-769750 caused hepatobiliary toxicity, identifying the diol and possibly its downstream hydroxyacid (BMS-800754) metabolite as the toxic species. Rat liver gene expression revealed treatment-related changes in hepatic transporters and induction of oval cell-specific genes including deleted malignant tumor 1 (Dmbt1). The metabolites did not alter hepatic transporter activities, suggesting that transporter-mediated cholestasis was not involved. Because injury to biliary epithelium can result in adaptive hyperplasia, rat biliary epithelial cells (BECs) were isolated and exposed to the oxidative metabolites. BMS-769750 was cytotoxic to BECs, but not rat hepatocytes, suggesting a role of the diol in biliary epithelial injury. BMS-800754 was cytotoxic to rat hepatocytes therefore its contribution to hepatocyte injury in rats is a possibility. Induction of Dmbt1 in rat BECs was investigated because of its role in hepatic progenitor cell differentiation/proliferation during injury. Dmbt1 mRNA was induced by BMS-769750, but not BMS-800754 in BECs; this induction and cellular injury was confirmed with diol metabolites formed by other compounds with the same hepatobiliary liability. In conclusion, hepatobiliary injury by thienopyrimidinone MCHR1 antagonists was driven through a CYP-mediated bioactivation pathway. Induction of Dmbt1 mRNA coupled with cellular injury suggests that injury of biliary epithelium may be the first step toward an adaptive proliferative response causing BDH by these compounds.
INTRODUCTION
Biliary epithelial cells (BECs/cholangiocytes) make up only 3%-5% of the total liver mass but have an important physiological role in bile formation and composition (Mizuguchi et al., 2011; Yang et al., 2010) . Cholangiocytes line the extra-hepatic (large) and intra-hepatic (small) ducts of the biliary tree and are essential in formation and drainage of bile from hepatocytes into the gall bladder. During this process, the cells maintain systemic and biliary homeostasis by clearing xenobiotics, recirculating bile acids, reabsorbing intestinal lipids, and maintaining intracellular pH through a network of transporters. BECs also play a role in immune regulation and defense illustrated by expression and function of various molecules involved in innate immunity (eg, Toll-like receptors and cytokines) and adaptive immunity (eg, MHC and the co-stimulatory factors CD40, CD80, and CD86).
BECs are targets of human liver diseases (Yang et al., 2010 ) and drug-induced injury (Osterreicher and Trauner, 2012) . These cholangiopathies include autoimmune disorders (eg, primary sclerosing cholangitis and autoimmune cholangitis), vanishing bile duct syndrome, and biliary atresia. Various drugs have been implicated in biliary toxicity (Geubel and Sempoux, 2000) with clinical symptoms and serum chemistries indicative of hepatocholangiolitis, cholestasis, and jaundice. Flucloxacillin and carbamazepine are examples of drugs that cause vanishing bile duct syndrome secondary to severe cholestasis (Davies et al., 1994; Moradpour et al., 1994) . Cholestasis is characterized by dysregulation in disposition or secretion of bile that is often associated with elevation in circulating bilirubin, bile acids, and cholesterol, and in some instances by bile-duct obstruction (Padda et al., 2011; Pauli-Magnus and Meier, 2006) . Inhibition of hepatic transporters and direct injury to biliary epithelium are examples of direct or indirect mechanisms by which drugs may induce cholestasis (Cheon, 2012; Dietrich and Geier, 2014; Rodrigues et al., 2014; Stieger and Geier, 2011) . Alphanaphthylisothiocynate (ANIT) (Becker and Plaa, 1965a, b; Desmet et al., 1968; Kossor et al., 1993) and methylenedianiline (Kopelman et al., 1966; Zhang et al., 2006) are examples of extensively characterized xenobiotics that cause direct biliary injury accompanied by cholestasis; both compounds also cause bile duct hyperplasia (BDH) considered secondary to injury to biliary epithelium (Church et al., 2016) . Insult to biliary epithelium may be caused by a direct effect of a compound and/or metabolite or could be secondary to cholestasis (probably from exposure to toxic bile acids). Biliary injury can progress to an adaptive proliferative response of biliary epithelial cells and bile ducts resulting in BDH. In animals, chronic biliary injury may also progress to fibrosis or cancer. Isolated BDH that occurs in the absence of biliary injury has also been described (Hailey et al., 2013; Luo et al., 2014) . In this manuscript BDH and biliary hyperplasia will be used synonymously.
Although the incidence of drug-induced biliary injury and BDH is rare, the potential for translation of these findings in man coupled with lack of predictive biomarkers supports minimizing the risk for such a liability during drug development. While screening small molecule antagonists of MCHR1 in rats, hepatobiliary toxicity was observed by thienopyrimidones exemplified by BMS-773174 administered as a valine ester prodrug to release the parent BMS-772486. This work describes in vivo and in vitro approaches taken to investigate the mechanism of biliary toxicity using BMS-773174 as a tool molecule.
MATERIALS AND METHODS

Materials
1-Aminobenzotriazole, sodium bicarbonate, D-glucose, forskolin, triiodothronine, dexamethasone, glycylclycine, fast blue BBN were purchased from Sigma-Aldrich (St. Louis, Missouri). Nuserum IV, epidermal growth factor (EGF), bovine pituitary extract, ITSþ premix collagen coated flasks, plates, and chamber slides were from BD biosciences (San Jose, California). DMEM/ F12 culture medium powder and gentamicin were purchased from Life Technologies (Grand Island, New York). All compounds identified with Bristol-Myers Squibb (BMS) numbers were synthesized internally and were !99% pure.
In vivo studies
All animals were maintained at Bristol-Myers Squibb facilities in accordance with the guidelines established by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and all protocols were approved by the Bristol-Myers Squibb Animal Care and Use Committee (ACUC). Male Sprague-Dawley (SD) rats (Charles River Laboratories, Bar Harbor, Maine) on normal Harlan-Teklad 2018C diet (Harlan-Teklad Laboratories, Madison, Wisconsin) were dosed in groups of 4 to 6 rats per group at 8 weeks old with 30 mg/kg/day of BMS-773174 orally for 3 or 7 days in 0.5% aqueous methyl cellulose/0.1% Tween80 with or without daily administration of ABT at 50 mg/kg/day (7 days only) given by intraperitoneal injection in 0.9% saline (2h prior to oral dosing). The study with 3 daily dosing of BMS-773174 was conducted on a different occasion from the study with 7 daily dosing and was not an interim evaluation from the longer duration study. Rats were euthanatized with isoflurane 24h after the last dose, and livers were collected and processed for microscopic evaluation or drug concentrations. Blood (0.5 mL) was collected into tubes with or without anticoagulant (K 2 ETDA), centrifuged at 1000 Â g for 10 minutes at approximately 4 C, and processed to plasma for drug level measurements or serum. Serum chemistry analytes included alanine transaminase (ALT), alkaline phosphatase (ALP), and sorbital dehydrogenase (SDH) activities, as well as total bile acids (TBA), and total bilirubin (BILI), all measured with an Advia 1800 (Siemens Healthcare).
Histopathology including immunohistochemistry
Liver samples were fixed in 10% formalin, routinely processed to paraffin blocks, sectioned at 6 microns, and stained with hematoxylin and eosin prior to examination by light microscopy. Additional samples were sectioned at 5 microns, mounted onto Superfrost Gold Plus glass slides (Erie Scientific, Portsmouth, New Hampshire) and stained for Ki-67 antigen by immunohistochemistry. Sections were subjected to Heat Induced Epitope Retrieval using Target Retrieval Citrate Solution, pH 6.0 (Dako North America, Carpinteria, California). A rabbit monoclonal anti-Ki67 antibody (Vector Labs, Burlingame, California) was used at 1:700 for 1h at room temperature. The primary antibody was detected using an anti-rabbit polymer system directly conjugated to HRP (BioCare Medical, Concord, California) and visualized as a brown precipitate with diaminobenzidine (DAB) (Dako North America, Carpinteria, California). Sections were counterstained with Hematoxylin, Gills Formula (Vector Labs, Burlingame, California), dehydrated, cleared and permanently mounted. Staining was quantified using the multistain high resolution assay technology of semi-automated image analysis system, the Ariol SL-50 TM (Applied Imaging
Corp., San Jose, California). Regions of Interest (ROI) for analysis were selected at 200Â magnification to include hepatocytes and a portal triad and the same number of ROIs of exactly the same size was counted per liver section (3 sections per animal). Color and shape classifiers were trained to identify brown pixels and quantify Ki67 positive staining. A second set of classifiers was trained to identify blue pixels and quantify cell nuclei that did not stain with the antibody. A proliferative index was determined by dividing the number of Ki-67 positive nuclei by the total number of positive and negative nuclei within each ROI and multiplying by 100.
Bioanalytical measurement of compounds and their metabolites in plasma and liver
Aliquots (100 mL) of plasma and standard/QC samples were treated with acetonitrile (250 mL) containing internal standard followed by vortex mixing for 1 minute. The supernatant was then separated from the precipitated proteins by a 15-min centrifugation at 3000 Â g and transferred to a 96-well plate. An aliquot (5 mL) was injected onto the high-performance liquid chromatography (HPLC) column for LC/MS/MS-based analysis. A few milligrams of liver were homogenized and processed for analysis using the protein-precipitating procedure described above for plasma. If dilutions were required, an aliquot of the sample was diluted into the respective matrix. For liver, an aliquot was first diluted into blank plasma and then treated as described above. The HPLC system consisted of 2 LC10ADvp pumps with a SCL-10Avp System Controller (Shimadzu, Columbia, Maryland) and a CTC Analytics HTS PAL autosampler (Switzerland) equipped with cooling stack that maintained samples at 10 C during analysis. The analytical column used was a Luna C18(2) 50 mm Â 2.00 mm, 3 mm 100 Å , (Phenomenex, Torrance, California) at room temperature. The mobile phase, which consisted of 5 mM ammonium acetate and 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B), was delivered at a flow rate of 0.3 mL/min. Concentration of each compound and its metabolite were determined from their respective standard curves fitted with a linear regression weighted by reciprocal concentration squared (1/X 2 ).
Liver gene expression
Samples of the right lateral lobe were collected following treatment of rats with vehicle control or BMS-773174 (30 mg/kg/day) for 3 days (n ¼ 4 per group) or 7 days (n ¼ 6 per group) or BMS-773174 (30 mg/kg/day) þ ABT (50 mg/kg/day) for 7 days (n ¼ 6 per group) with necropsies 24 hours after last dose on Days 4 and 8, and stored at -70 C until RNA isolation. HT Rat Focus array plate (Affymetrix, Inc., Santa Clara, California). Microarray data were normalized by the robust multi-array averaging (RMA) method using in-house-developed software. The normalized data were then analyzed for significantly altered genes using one-way ANOVA followed by a Benjamini-Hochberg false discovery rate (FDR) correction because the study with 3 daily dosing of test compound, and microarray analysis, was conducted on a separate occasion from the study with 7 daily dosing. Significance was considered at P < .01 following FDR correction. Gene ontology analysis was limited to transcripts that were FDR corrected with P < .01. All array computations (ANOVA, FDR, gene ontology) were conducted using ArrayStudio V R software (version 9, OmicSoft V R , Cary, North Carolina).
In Vitro Methods
Transporter assays Hepatic transporter assays were conducted by Qualyst Inc (Research Triangle Park, North Carolina) using B-CLEAR-RT V R technology for rat as described by Kemp et al. (2005) . BMS-772486 (parent) and its oxidative metabolites BMS-759750 and BMS-800754 were tested at a pre-determined optimal concentration of 10 lM to evaluate their potential to alter the hepatobiliary disposition of d 8 -taurocholate. Bosentan (50 mM) was used as a positive control and d 8 -taurocholate was used as a probe substrate for evaluating hepatobiliary transporter activity (uptake and efflux) of bile acids. D 8 -taurocholate was quantitated by LC/MS analysis. Biliary excretion index (BEI) and biliary clearance (Cl biliary ) were determined as previously described (Kemp et al., 2005) .
Biliary epithelial cell isolation and culture Rat BECs were isolated from a male SD rat (Charles River Laboratories, Bar Harbor, ME; 250-300 g) and maintained using the methods of Yang et al. (Yang et al., 1993) and Okamoto et al. (Okamoto et al., 1995) . All procedures were approved by ACUC guidelines within Bristol-Myers Squibb Co. Rats were anesthetized with sodium pentobarbital and perfused with collagenase (Worthington Biochemical, Lakewood, New Jersey) for 20 min to loosen hepatocytes which were then shaken off the liver. The remaining biliary tree was fragmented, digested with pronase (Sigma-Aldrich, St. Louis, Missouri) and seeded on a collagen gel (BD Biosciences, San Jose, California) sandwich in a 6-well plate. After 8 days, the fragments formed sacs filled with cells which were released by trypsinization and cultured on top of collagen gel in a 6-well plate with DMEM/F12, 10% Nuserum IV, 20 ng/ml EGF, 12.5 lg/ml bovine pituitary extract, 3 lM forskolin, 5 nM triiodothyronine, 1 lM dexamethasone, 50 mg/ml Gentamicin, and 1% ITSþ premix. BECs were cultured on collagen IV coated flasks and could be propagated for up to 20 passages while maintaining their epithelial characteristics. Stock cells of BECs from several passages were frozen in liquid Nitrogen. BEC's from passages 5 to 20 were characterized and cells from passage 8 were utilized for viability assays.
Transmission electron microscopy (TEM) of BEC Cells in 96-well plates were processed for transmission electron microscopy (TEM) in situ. They were briefly rinsed with PBS and fixed with 2%/2% paraformaldehyde/glutaraldehyde in PBS, further fixed with 1% osmium tetroxide, dehydrated with ethanol and embedded in PolyBed 812 V R . Ultrathin sections ($60 nm)
were cut, stained with uranyl acetate and lead citrate, examined with an FEI Tecnai G2 Spirit BioTwin transmission electron microscope, and images were collected with an AMT image capture system.
Histochemical analysis
Qualitative histochemical analysis of cultured BECs for c-glutamyl transpeptidase activity (GGT) was performed according to the method of Rutenburg et al. (1969) using c-Glutamyl-4-methoxy-2-naphthylamide (Sigma-Aldrich, St. Louis, Missouri). BECs were plated on collagen IV coated 2-well chamber slide ($100 000 cells/well) for 48 h prior to characterization. Culture medium was aspirated and washed with calcium and magnesium free phosphate-buffered saline (PBS) and the cells fixed in cold acetone for 5 min and air dried. The slide was incubated with a drop of freshly prepared substrate incubation medium containing c-glutamyl-4-methoxy-2-naphthylamide, 0.1 M TrisHCl (pH 7.4), glycylglycine and N-(4-amino-2,5-diethoxyphenyl) benzamide for 1 h at 37 C. The slide was rinsed with Trisbuffered saline (TBS) and incubated in 0.1 M cupric sulfate for 2 min followed by a second rinse, then air-dried, and coverslipped in glycerol:PBS (9:1). Cells positive for GGT stained red or reddish-orange by qualitative assessment.
Immunohistochemistry
Primary rat BECs grown in collagen coated 2 chambered slides were fixed in cold acetone and endogenous IgG and nonspecific background were blocked with Rodent Block R (Biocare Medical, Concord, California). This was followed by incubation with mouse anti-cytokeratin 7 (Abcam, Cambridge, Massachusetts) or goat anti-Asbt (Santa Cruz Biotechnology, Dallas, Texas) or rabbit anti-Mrp3 (Abcam, Cambridge, Massachusetts) for 1 h at room temperature (RT). The antibody/ antigen complex was detected with rabbit polymer detection system conjugated to horseradish peroxidase (Biocare Medical, Concord, California and Dako North America, Carpenteria, California) and finally diaminobenzediene (Dako North America, Carpenteria, California) resulting in a brown precipitate wherever positive immune expression occurred. Sections were then counterstained with hematoxylin (Vector Labs, Burlingame, California), dehydrated, cleared with xylene and permanently mounted under cover glass.
mRNA Expression in BECs
Total RNA from BECs, rat liver, and ileum were extracted and purified using RNeasy Mini Kit (Qiagen, Valencia, California) according to the manufacturer's instruction. RNA (2 mg) was reverse transcribed using high capacity cDNA kit (Life Technologies, Grand Island, New York). 20 ng of cDNA was subjected to realtime PCR on 7900HT using SYBR V R Green RT-PCR reagent kit (Life Technologies, Grand Island, New York). The expression of drug metabolizing enzymes, transporters and deleted malignant tumor 1 (Dmbt1) was determined with primers outlined in Supplemental data, Table 1 . 18s rRNA was used as an endogenous control to normalize mRNA target for the differences in the amount of total RNA added to each reaction. Relative quantitation of mRNA was calculated by the comparative C T method (DDC T ) (Livak and Schmittgen, 2001) . For Dmbt1 transcription experiments, BEC's from passages 8 to 14 were seeded (300 000/ well) on collagen I-coated 12-well plates and after 6h were exposed to 10 mM compounds for 24 h. RNA was isolated and 50 ng of cDNA was subjected to real-time PCR as above.
Viability assays
BECs (10 000/well) from passages 8 were seeded in collagen Icoated black 96-well plates and allowed to grow for 3 days before treatment with compound for 72 h. 
RESULTS
Hepatobiliary Toxicity by BMS-772486 in Rats
Marked hepatobiliary toxicity was observed in male rats exposed to BMS-772486 administered as the valine ester prodrug BMS-773174 ( Figure 1A ) at 30 mg/kg/day for 7 daily doses. Microscopically, hepatobiliary lesions were characterized by hypertrophy, hyperplasia, and individual cell necrosis of hepatocytes and markedly proliferated bile ducts lined by hyperplastic epithelium ( Figure 2B , Table 2 ). Hyperplastic bile ducts were distended by eosinophilic material, infiltrated and surrounded by inflammatory cells and partially encompassed by fibro-vascular tissue. There were no differences in microscopic findings in the liver following administration of 3 daily doses of compound (data not shown) in a study conducted to investigate the onset of the toxicity. This is supported by similar increases in transaminases, bilirubin, and bile acids following administration of 3 or 7 doses of BMS-774174 (Table 1) . Ki-67 immunohistochemistry illustrated the proliferative response of bile duct epithelial cells and hepatocytes (Figs. 2F and G) ; the proliferative index in portal regions was approximately 7-fold greater in treated rats (19.3%) than control rats (2.7%) receiving vehicle ( Figure 2H ). Hepatobiliary lesions and serum biochemistry changes were prevented by co-treatment with the nonselective cytochrome P450 (CYP) inhibitor 1-aminobenzotriazole (ABT) indicating that biotransformation is necessary for hepatobiliary toxicity ( Figure 2C , Table 1 ). In addition, there were appreciable liver concentrations of the parent BMS-772486, diol metabolite (BMS-759750), and hydroxyacid metabolite (BMS-800754), and significant liver accumulation of the diol and hydroxyacid compared to plasma (Table 2 ). Oral administration of the divaline ester prodrug BMS-800555 ( Figure 1A ) to release the diol metabolite (BMS-759750) induced pronounced hepatobiliary toxicity (data not shown) with a similar microscopic presentation as BMS-773174 identifying the diol as the penultimate or ultimate toxic metabolite. Additional thienopyrimidone compounds that formed similar oxidative metabolites as described for BMS-773174 also caused biliary lesions in rats (Supplemental data, Table 2 ), and BMS-814580 ( Figure 1B ) designed not to be bioactivated was not hepatotoxic in rats (Supplemental data, Table 2 ).
Liver Gene Expression Profiling Following Exposure to BMS-772486 in Rats
Gene expression studies were conducted to elucidate the mechanism and/or understand the pathways involved in biliary toxicity following treatment with BMS-771374. Significantly changed transcripts and gene ontology analysis results are listed in Supplemental data, Table 3 . Overall, the gene expression changes were coincidental with lesions after 3 or 7 daily doses, and changes were generally associated with transcripts involved in cholesterol biosynthesis, hepatic transport, and FXR-dependent regulation. Several genes identified as oval cell or cholangiocyte-specific (Yovchev et al., 2008) were upregulated, including secretin receptor, EpCAM, CD44, CD24 and Ck19 (Table 3) . Additionally, Dmbt1 (deleted in malignant brain tumor 1), an oval cell specific marker, was increased $3-fold following treatment with BMS-773174 but was unchanged with co-administration with ABT or following exposure to the nonhepatotoxic BMS-814580 (Data not shown).
The Effect of BMS-772486 and Its Oxidative Metabolites on Hepatocyte Transporter Function
Cholangiopathies including biliary hyperplasia may occur secondary to cholestasis resulting from inhibition of hepatic transporters (Padda et al., 2011) . A limited in vivo evaluation revealed small changes in biliary flow and bile acid/bile composition (data not shown) following exposure of rats to the parent compound BMS-772486. There were also some treatment-related changes in expression of hepatic transporters (Supplemental data, Table 3 ) in rats, which prompted an evaluation of transporter function as a potential mechanism for biliary toxicity observed in vivo. In rat hepatocyte sandwich cultures, BMS-772486 and its oxidative metabolites BMS-759750 BMS-800754 had no effect on disposition of the probe substrate d 8 -taurocholate (Table 4) suggesting lack of an effect on both uptake and efflux transporters, while the positive control bosentan significantly inhibited both efflux and uptake of the probe substrate. These same compounds had no effect on taurocholate uptake into human hepatocytes, human BSEP vesicles, or estrone-3-sulfate uptake into HEK293 cells expressing human organic anion transporter 2B1 (data not shown).
Characterization of Biliary Epithelial Cells to Test BMS-772486 and Its Metabolites
Injury to biliary epithelium can result in an adaptive proliferative response. To examine whether hyperplasia mediated by BMS-772486 was secondary to biliary injury, the compound and its oxidative metabolites ( Figure 1A ) were tested in primary rat biliary cells. The cells were initially characterized to ensure that they maintained physiologically relevant physical and functional characteristics. This characterization is summarized in Supplemental data, Figure 1 . Briefly, cultured BECs were polarized, formed tight junctions, and had numerous microvilli on the apical side consistent with their properties in vivo and cglutamyl transpeptidase (GGT) and cytokeratin 7 (CK7) expression was maintained up to 60 passages. The cells expressed Phase II enzymes (Ugt1a1, Ugt1a2, Ugt1a6, Gstyc2) and transporters (Mrp3, Asbt, Abcg1), but not Cyp1a2 or Cyp3a1 (Supplemental data, Table 4 ). The cholangiocyte phenotype of rat BEC cells coupled with abundant expression of relevant enzymes and transporters deemed the cells suitable for mechanistic studies. Since BECs do not express Cyps, any effect of oxidative metabolites had to be assessed directly with synthesized metabolites.
In Vitro Toxicity and Induction of Dmbt1 by BMS-772486 and Its Oxidative Metabolites in Primary BECs
Although the in vivo effect is biliary hyperplasia, there was no direct effect of BMS-772486 or its metabolites on BEC proliferation in vitro (data not shown). However, the diol metabolite BMS-759750 was cytotoxic to BECs ( Figure 3A) , while the parent BMS-772486 and the hydroxyacid metabolite BMS-800754 were not toxic to BECs. To address specificity in the response, the compounds were incubated with primary rat hepatocytes, and cytotoxicity determined. Interestingly, the diol metabolite was not cytotoxic to primary rat hepatocytes, however, its downstream metabolite, BMS-800754, was cytotoxic to hepatocytes ( Figure 3B) ; this shows specific injury by the diol metabolite in BECs, and a possible contribution of the hydroxyacid metabolite to hepatocyte injury. Additional studies were conducted in primary rat BECs to investigate the effect of the oxidative metabolites of BMS-772486 on Dmbt1 mRNA expression. These studies focused on Dmbt1 because of reports that its increased expression activates hepatic progenitor cell proliferation and differentiation during injury and repair (Bisgaard et al., 2002; Deng et al., 2012) , as well as findings suggesting that it may be a biomarker for BDH based on studies conducted with compounds that also caused biliary hyperplasia in rats (Watson et al., 2006) . The diol metabolite BMS-759750 significantly induced expression of Dmbt1 mRNA, while the hydroxyacid metabolite BMS-800754 had no effect ( Figure 3C ) on its expression, in concordance with the viability data. This induction was not unique to BMS-759750 because the diol metabolites of additional thienopyrimidones that caused biliary hyperplasia in rats also induced Dmbt1 mRNA and injury in rat BECs (Supplemental data, Table 2 ). BMS-814580, a compound that is not bioactivated and is not hepatototoxic did not induce Dmbt1 mRNA or cause cytotoxicity in vitro, while methapyrilene, known to cause biliary hyperplasia in rats (Watson et al., 2006) , also induced Dmbt1 mRNA in rat BECs (Supplemental data, Table 2 ).
DISCUSSION
Non-neoplastic proliferation of bile ducts characterized by hyperplasia and other progressive lesions, such as fibrosis has been described as a spontaneous lesion in rats and mice (Hailey et al., 2013; Thoolen et al., 2010) . Biliary proliferative lesions can also be induced in rats by chemicals and drugs, and the clinical relevance or adverse nature of this finding is discussed by Hailey et al. (2013) . Biliary proliferative lesions associated with cholestasis or progression to fibrosis is considered adverse. There are varying opinions on the clinical relevance of nonclinical biliary hyperplasia. For the most part, biliary hyperplasia accompanied by serum markers indicative of hepatobiliary injury, as described in this paper, is considered to be a concern for clinical hepatotoxicity, while clinical relevance of hyperplasia without accompanying injury markers or other microscopic changes in liver remains uncertain.
In the present studies, potential for clinical hepatotoxicity was a concern based on the rapid onset and severity of biliary hyperplasia that was accompanied by increases in liver injury markers. Single-cell necrosis of hepatocytes and increased liver enzymes following exposure to BMS-772486 (administered as the valine ester prodrug BMS-773174) in rats may have been a result of direct injury to hepatocytes or secondary to biliary injury, ie, bystander effect. Based on concerns of clinical risk of hepatotoxicity it was imperative to understand the mechanism of toxicity in order to select compounds with an improved profile. Toxicity was caused by CYP P450-mediated bioactivation because it was prevented by the CYP inhibitor ABT and confirmed by hepatobiliary toxicity following administration of the oxidative diol metabolite as a prodrug to rats. Biliary toxicity following exposure to BMS-772486 was unrelated to target pharmacology because toxicity was mitigated by structural alterations that prevented bioactivation. This metabolic activation was expected to be conserved across species hence the rationale to terminate the development of these molecules.
Biliary hyperplasia may occur secondary to cholestasis, and because cholestasis was noted in rats exposed to BMS-772486, and hepatic transporter mRNAs were upregulated in vivo, inhibition of hepatic transporter activity by parent and oxidative metabolites was investigated. There were no effects on uptake or efflux transporter activities by all compounds tested confirming that transporter-mediated cholestasis was not involved as a mechanism leading to biliary hyperplasia.
Because injury to biliary epithelium is an insult that precedes adaptive hyperplasia, also supported by time course studies that have been conducted with tool compounds, such as ANIT (Church et al., 2016) , the effect of the diol (BMS-759750) and hydroxyl acid (BMS-800754) metabolites on rat BECs and rat hepatocytes was investigated. The diol metabolite was cytotoxic to BECs, but not to rat hepatocytes, corroborating in vivo findings that BMS-759750 is a key contributor to hepatobiliary toxicity caused by BMS-772486. This finding was not unique to BMS-759750 because the diol metabolites of additional thienopyrimidone compounds that cause BDH in rats also caused cytotoxicity in rat BECs. The hydroxyacid metabolite had no effect on BECs, but was cytotoxic to rat hepatocytes, thus its contribution to hepatotoxicity in vivo cannot be ruled out. BMS-814850, which was structurally modified not to be bioactivated did not cause hepatobiliary toxicity in rats and was also not toxic to BECs. The in vitro studies suggest that injury to biliary epithelium by the diol metabolite may be a key step toward an adaptive BDH.
Liver gene expression identified a panel of oval cell or cholangiocyte-specific genes that were upregulated following A, BEC's from passage 8 were seeded on collagen-coated plates (10 000 cells/ well) and allowed to grow for 3 days before they were exposed to varying concentrations of BMS-772486, BMS-800754, and BMS-800754 and viability assessed as described in "Materials and Methods". Data shows Mean 6 SD of 3 separate experiments. B, Primary rat hepatocytes were seeded (100 000/well) in clear bottom 96-well plates, allowed to rest for 24 h, prior to treatment with varying concentrations of BMS-772486, BMS-800754, and BMS-800754 and viability assessed as described in "Materials and Methods" Data shows Mean 6 SD of 3 separate experiments from hepatocytes isolated from 3 different rats. C, BECs from passages 8-14 were seeded on collagen I coated 12-well plates (300 000 cells/well) and after 6 h exposed to 10mM BMS-759750 and BMS-800754 for 24 h after which mRNA was isolated and Dmbt1 mRNA measured as described in "Materials and Methods". Structures of all compounds are shown in Figure 1 Data are represented as Mean 6 SD, N ¼ 3 separate experiments. **P 0.01; ****P 0.0001 compared to vehicle (t-test).
exposure to BMS-772486. These genes can be used to signify differentiation/proliferation of oval cells to cholangiocytes because these cells are bipotential and can be activated to proliferate and differentiate into hepatocytes or biliary epithelial cells (Yovchev et al., 2008) . Treatment-related induction in this panel of genes may inform on the differentiation fate of oval cells following hepatobiliary injury and also as markers for proliferation of cholangiocytes (ie, BDH). Cytokeratin 19 (CK19) and epithelial cell adhesion molecule (EpCAM) are abundantly expressed on cholangiocytes hence their induction following treatment with BMS-773174 results from an increased number of bile ducts during BDH. These genes were considered not suitable for use as markers for BDH in vitro because proliferation of bile ducts cannot be emulated in rat BECs. CD44, a transmembrane glycoprotein receptor, is not expressed in normal BECs and hepatocytes, but is upregulated in biliary disease and in cholestatic injury (Cruickshank et al., 1999; He et al., 2008) . CD44 is induced during cholestasis, upon which binding of its ligand, hyaluronic acid, a component of the extracellular matrix, triggers biliary hyperplasia (He et al., 2008) . This suggests that induction of CD44 mRNA following treatment with BMS-773174 contributes to biliary hyperplasia but as a secondary mechanism to biliary pathology rather than from a direct effect of binding of parent molecule or metabolites to CD44. This marker was therefore also not considered as suitable for in vitro evaluations by these compounds. Investigating induction of liver Dmbt1 (deleted in malignant brain tumor 1) mRNA was of particular interest because it is induced during proliferation of oval cells/cholangiocytes in rodents (Bisgaard et al., 2002) and humans (Deng et al., 2012) , and is thought to play a role in proliferation and differentiation of oval cells during injury and repair. Watson et al. (Watson et al., 2006) also identified Dmbt1 as a potential biomarker for BDH by toxicogenomics and immunoblot analysis in studies using proprietary compounds and tool molecules, such as methapyrilene, that caused BDH in rats, and a set of negative controls that were not hepatotoxic. In the present studies, Dmbt1 mRNA was induced by the diol BMS-759750, but not the hydroxyacid metabolite in rat BECs. This induction was also observed with other diol metabolites of thienopyrimidone compounds that induced biliary toxicity in rats, and was not induced by BMS-814850 that was designed not to be bioactivated. It can therefore be hypothesized that hepatobiliary injury-induced expression of Dmbt1 mRNA initiates an adaptive proliferative/ differentiation response of oval cells/cholangiocytes resulting in BDH.
In conclusion, hepatobiliary injury by thienopyrimidinone MCHR1 antagonists was driven through a CYP-mediated bioactivation pathway. There was no role for hepatic transporter inhibition as a mechanism for BDH by these compounds. Cytotoxicity by diol metabolites coupled with induction of Dmbt1 mRNA suggests that insult to biliary epithelium may be a key step toward an adaptive proliferative response causing BDH by these compounds. It can be inferred from the in vitro studies that assessment of cellular injury and induction of Dmbt1 mRNA in primary rat BECs may be useful endpoints for selecting compounds with reduced potential for causing BDH in rats.
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